» Articles » PMID: 29113203

Distribution of Uridine Diphosphate Glucuronosyltransferase 1A Polymorphisms and Their Role in Irinotecan-induced Toxicity in Patients with Cancer

Overview
Journal Oncol Lett
Specialty Oncology
Date 2017 Nov 9
PMID 29113203
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Uridine diphosphate glucuronosyltransferase 1A (UGT1A1), which affects irinotecan metabolism, has been associated with severe adverse reactions in patients with cancer treated with irinotecan. However, neither large-scale analysis of the distribution of UGT1A1 polymorphisms, nor standardized assessment of how UGT1A1 polymorphisms affect irinotecan treatment has been performed in China. The aim of the present study was to investigate the distribution of UGT1A1 polymorphisms (*28 and *6) in 2,093 Chinese patients with cancer who were treated with irinotecan from more than 15 hospitals in Shandong, to examine how the coexistence of UGT1A1*6 and UGT1A1*28 alleles may be able to predict toxicities induced by irinotecan in 105 of the patients, and to search for other relevant risk factors. The distribution of the genotypes was as follows: TA/TA (1,601, 76.5%), TA/TA (463, 22.1%) and TA/TA (29, 1.4%) for UGT1A1*28 (n=2,093); and G/G (286, 66.4%), G/A (124, 28.8%) and A/A (21, 4.9%) for UGT1A1*6 (n=431). The most frequent severe hematological toxicity was neutropenia, and the predominant non-hematological toxicities were diarrhea and cholinergic syndrome. In toxicity comparisons, grade 3-4 leukopenia and neutropenia were significantly higher in TA/TA compared with TA/TA (P<0.05). The UGT1A1*6 polymorphism was associated with a higher risk of severe diarrhea and total adverse drug reactions (P<0.05). Logistic regression showed that the UGT1A1*6 genotype was an independent predictor of severe diarrhea. These findings suggested that the UGT1A1*28 and UGT1A1*6 genotypes may be associated with irinotecan-induced severe toxicity, and clarified the clinical importance of UGT1A1 polymorphisms, particularly UGT1A1*6, regarding irinotecan therapy in Chinese patients.

Citing Articles

Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.

Atasilp C, Biswas M, Jinda P, Nuntharadthanaphong N, Rachanakul J, Hongkaew Y Clin Transl Sci. 2022; 15(7):1613-1633.

PMID: 35506159 PMC: 9283744. DOI: 10.1111/cts.13277.


Sources of Interindividual Variability.

Lin Y, Thummel K, Thompson B, Totah R, Cho C Methods Mol Biol. 2021; 2342:481-550.

PMID: 34272705 DOI: 10.1007/978-1-0716-1554-6_17.


Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.

Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Sirilerttrakul S, Chamnanphon M Sci Rep. 2020; 10(1):13486.

PMID: 32778670 PMC: 7417535. DOI: 10.1038/s41598-020-70351-0.


Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial.

Deng C, Lou Y, Gao Y, Deng B, Su F, Jia L Trials. 2020; 21(1):370.

PMID: 32357899 PMC: 7193543. DOI: 10.1186/s13063-020-04275-5.


Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.

Kanbayashi Y, Ishikawa T, Kanazawa M, Nakajima Y, Tabuchi Y, Kawano R Med Oncol. 2018; 35(6):82.

PMID: 29705823 DOI: 10.1007/s12032-018-1142-3.

References
1.
Yamamoto N, Takahashi T, Kunikane H, Masuda N, Eguchi K, Shibuya M . Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Ther. 2008; 85(2):149-54. DOI: 10.1038/clpt.2008.152. View

2.
Lu Y, Huang X, Wu X, Cao J, Liu J, Wang L . Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Asian Pac J Cancer Prev. 2014; 15(7):3335-41. DOI: 10.7314/apjcp.2014.15.7.3335. View

3.
Innocenti F, Ratain M . "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 2004; 75(6):495-500. DOI: 10.1016/j.clpt.2004.01.011. View

4.
Mathijssen R, van Alphen R, Verweij J, Loos W, Nooter K, Stoter G . Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001; 7(8):2182-94. View

5.
Stewart C, Panetta J, OShaughnessy M, Throm S, Fraga C, Owens T . UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol. 2007; 25(18):2594-600. DOI: 10.1200/JCO.2006.10.2301. View